This publication does not concern the award of a public contract within the meaning of the Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of informing interested pharmaceutical entrepreneurs as broadly as possible, this notice will be made in the supplement to the Official Journal of the European Union. The process name “open procedure” used in the context of this publication text (section IV.1.1) is due to the specifications of the announcement form. This and the use of the medium “TED” does not involve any submission under procurement regulations whose validity is not mandatory by law or procurement regulations. It is a framework agreement with an option to join, which relates to various active substances.

The subject of the contract are medicinal products containing the active ingredient combination beclometasone dipropionate and formoterol in the dosage form metered-dose inhaler and with an active strength of 100/6 micrograms.

Medicines containing the active substance eletriptan are the subject of the contract.

The subject of the contract are medicinal products containing the active ingredient enoxaparin sodium in the standard size N2 and the potency of 100mg.

Medicines containing the active substance epoetin beta are the subject of the contract.

Medicines containing the active substance epoetin zeta are subject to the contract.

Medicines containing the active substance follitropin beta are subject to the contract.

Medicines containing the active substance goserelin are the subject of the contract.

The subject of the contract are medicinal products containing the active ingredient granisetron in the dosage form ILO.

The subject of the contract are medicinal products that contain the active ingredient granisetron in the dosage form of a patch transdermal.

Medicines containing the active substance immunoglobulin G from humans are the subject of the contract.

Medicines containing the active substance interferon beta-1a (Avonex®) are subject to the contract.

The subject of the contract are medicinal products containing the active ingredient combination beclometasone dipropionate and formoterol in the dosage form metered-dose inhaler and with an active strength of 200/6 micrograms.

Medicines containing the active substance natalizumab in an intravascular dosage form are subject to the contract.

Medicines containing the active substance natalizumab in a subcutaneous dosage form are subject to the contract.

The contract covers medicinal products containing the active ingredient paliperidone in the dosage form DIS.

The subject of the contract are medicinal products that contain the active ingredient testosterone.

Medicines containing the active substance tinzaparin sodium are the subject of the contract.

Medicines containing the active substance tobramycin in the hard capsule dosage form with powder for inhalation are the subject of the contract.

The contract covers medicinal products containing the active ingredient tocilizumab in an intravenous dosage form.

The contract covers medicinal products containing the active ingredient tocilizumab in a subcutaneous dosage form.

The subject of the contract are medicinal products containing the active ingredient triamcinolone acetonide with the ATC code D07AB09.

Medicines containing the active substance trientin are the subject of the contract.

The contract covers medicinal products containing the active ingredient combination beclometasone dipropionate and formoterol in the dosage form of inhalation powder and with an active strength of 100/6 micrograms.

The subject of the contract are medicinal products containing the active ingredient combination beclometasone dipropionate and formoterol in the dosage form inhalation powder and with an active strength of 200/6 micrograms.

The subject of the contract are medicinal products containing the active ingredient combination beclometasone dipropionate and formoterol in the dosage form Inhalate.

The subject of the contract are medicinal products that contain the active ingredient budesonide in the dosage form metered-dose inhaler.

Medicinal products containing the active substance cyclosporine in an ophthalmic dosage form in single-dose pipettes are subject to the contract.

Medicines containing the active substance clonazepam are the subject of the contract.

Medicines containing the active substance dalteparin sodium are the subject of the contract.